Mark Foley is Chief Executive Officer of Revance Therapeutics, Inc. (RVNC). The company reported total compensation of $10,068,915 for fiscal year 2023.
| Salary | $720,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $8,810,731 |
| Option awards | $0 |
| Non-equity incentive plan | $522,720 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $15,464 |
| Total | $10,068,915 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Revance Therapeutics, Inc. filed March 21, 2024, accession 0001479290-24-000071.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2023 | Chief Executive Officer | $720,000 | $0 | $8,810,731 | $0 | $522,720 | $0 | $15,464 | $10,068,915 |
| FY2022 | Chief Executive Officer | $673,200 | $0 | $4,178,690 | $1,099,525 | $640,870 | $0 | $14,631 | $6,606,916 |
| FY2021 | Chief Executive Officer | $660,000 | $0 | $4,561,652 | $1,141,226 | $425,700 | $0 | $317,338 | $7,105,916 |
Totals as disclosed in each year's own compensation disclosure for Revance Therapeutics, Inc..
| Peer-group chief executive median | $8,526,943 |
|---|---|
| Difference from that median | $1,541,972 |
| Percentile within the disclosed peer group | 53rd |
| Peers with a disclosed figure | 15 |
Medians and percentiles are computed across the peer group Revance Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2023 total |
|---|---|---|
| Mark Foley this page | Chief Executive Officer | $10,068,915 |
| Dustin Sjuts | President | $4,581,630 |
| Tobin Schilke | Chief Financial Officer | $3,974,145 |
| Dwight Moxie | Chief Legal Officer | $3,528,145 |
The company's named executive officers for fiscal year 2023, and what it reported for each. See the full Revance Therapeutics, Inc. compensation brief.
Mark Foley's compensation sits inside Revance Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.